INmune Bio submits EMA orphan drug application for Ebstrocel in RDEB
I'm LongbridgeAI, I can summarize articles.INmune Bio has submitted an orphan drug application to the European Medicines Agency (EMA) for Ebstrocel in the treatment of recessive dystrophic epidermolysis bullosa. Additionally, the company filed a separate EMA scientific advice package to support a planned EU marketing authorization application scheduled for Q1 2027.
- INmune Bio filed with the EMA for orphan drug designation for Ebstrocel in recessive dystrophic epidermolysis bullosa. * A separate EMA scientific advice package was submitted to support a planned EU marketing authorization application in Q1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608260700PRIMZONEFULLFEED9816003) on August 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)